BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005;25 Suppl 1:S3-23. [PMID: 16227495 DOI: 10.1148/rg.25si055507] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
2 Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552-559. [PMID: 19957182 DOI: 10.1007/s00270-009-9752-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 5.2] [Reference Citation Analysis]
3 Ha BY, Ahmed A, Sze DY, Razavi MK, Simpson N, Keeffe EB, Nguyen MH. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther 2007;26:839-46. [PMID: 17767468 DOI: 10.1111/j.1365-2036.2007.03424.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
4 Oğul H, Kantarcı M, Genç B, Pirimoğlu B, Cullu N, Kızrak Y, Yılmaz O, Karabulut N. Perfusion CT imaging of the liver: review of clinical applications. Diagn Interv Radiol 2014;20:379-89. [PMID: 24834487 DOI: 10.5152/dir.2014.13396] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
5 Kim H, Park MS, Choi JY, Park YN, Kim MJ, Kim KS, Choi JS, Han KH, Kim E, Kim KW. Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI? Eur Radiol 2009;19:1744-51. [PMID: 19247666 DOI: 10.1007/s00330-009-1331-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 7.5] [Reference Citation Analysis]
6 Sun B, Zheng CS, Feng GS, Wang Y, Xia XW, Kan XF. Radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3255-3263 [DOI: 10.11569/wcjd.v19.i31.3255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Wang M, Yuan F, Wei Y, Xia C, Hu F, Song B. Hepatocellular Carcinoma: In Vivo Evaluation of Water Percentage as a Prognostic Biomarker Using Magnetic Resonance Imaging 3D-VIBE Multiecho Dixon. Cancer Biother Radiopharm 2018;33:300-6. [PMID: 30109954 DOI: 10.1089/cbr.2018.2483] [Reference Citation Analysis]
8 Görtz M, Galli U, Longerich T, Zöller M, Erb U, Schemmer P. De novo synthesis of C4.4A in hepatocellular carcinoma promotes migration and invasion of tumor cells. Oncol Rep 2017;38:2697-704. [PMID: 29048672 DOI: 10.3892/or.2017.5980] [Reference Citation Analysis]
9 Su R, Li Z, Li H, Song H, Bao C, Wei J, Cheng L. Grp78 promotes the invasion of hepatocellular carcinoma. BMC Cancer. 2010;10:20. [PMID: 20082722 DOI: 10.1186/1471-2407-10-20] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
10 Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Nucl Med Commun 2015;36:340-9. [PMID: 25563137 DOI: 10.1097/MNM.0000000000000257] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang S, Jiang K, Sun C, Lu H, Liu Y. Quantitative analysis of site-specific N-glycans on sera haptoglobin β chain in liver diseases. Acta Biochim Biophys Sin (Shanghai) 2013;45:1021-9. [PMID: 24103369 DOI: 10.1093/abbs/gmt110] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
12 Schmidt GP, Paprottka P, Jakobs TF, Hoffmann RT, Baur-Melnyk A, Haug A, Notohamiprodjo M, Baur-Melnyk A, Nikolaou K, Reiser MF, Rist C. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy. Eur J Radiol 2012;81:e269-76. [PMID: 21398060 DOI: 10.1016/j.ejrad.2011.02.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
13 Kim DH, Jeong SY, Lee SW, Lee J, Ahn BC. Solitary splenic metastasis from hepatocellular carcinoma detected on (18)F-FDG PET/CT. Clin Nucl Med 2015;40:e325-7. [PMID: 25546205 DOI: 10.1097/RLU.0000000000000659] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Kar F, Hacioglu C, Kacar S, Sahinturk V, Kanbak G. Betaine suppresses cell proliferation by increasing oxidative stress-mediated apoptosis and inflammation in DU-145 human prostate cancer cell line. Cell Stress Chaperones 2019;24:871-81. [PMID: 31368044 DOI: 10.1007/s12192-019-01022-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wu CF, Wu YJ, Liang PC, Wu CH, Peng SF, Chiu HW. Disease-free survival assessment by artificial neural networks for hepatocellular carcinoma patients after radiofrequency ablation. J Formos Med Assoc. 2017;116:765-773. [PMID: 28117199 DOI: 10.1016/j.jfma.2016.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
16 Chou CT, Chen RC, Lee CW, Ko CJ, Wu HK, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma by pre-operative CT imaging. Br J Radiol 2012;85:778-83. [PMID: 21828149 DOI: 10.1259/bjr/65897774] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
17 Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients. Hepatobiliary Pancreat Dis Int 2014;13:153-61. [PMID: 24686542 DOI: 10.1016/s1499-3872(14)60025-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
18 Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, Hosseinzadeh F, Iranikhah A, Shirian S. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int 2018;18:133. [PMID: 30214375 DOI: 10.1186/s12935-018-0624-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
19 Feng H, Li X, Chan V, Chen WN. Proteomics based identification of cell migration related proteins in HBV expressing HepG2 cells. PLoS One 2014;9:e95621. [PMID: 24763314 DOI: 10.1371/journal.pone.0095621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Peddu P, Huang D, Kane PA, Karani JB, Knisely AS. Vanishing liver tumours. Clin Radiol 2008;63:329-39. [PMID: 18275874 DOI: 10.1016/j.crad.2007.08.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
21 Chinnaratha MA, Campbell K, Mathias R, McCormick RJ, Woodman RJ, Wigg AJ. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis. J Gastrointest Cancer 2019;50:888-93. [PMID: 30345486 DOI: 10.1007/s12029-018-0171-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Du L, Lu X, Guan H, Yang Y, Gu M, Zheng Z, Lv T, Yan Z, Song L, Zou Y, Fu N, Qi X, Fan T. Development and evaluation of liquid embolic agents based on liquid crystalline material of glyceryl monooleate. International Journal of Pharmaceutics 2014;471:285-96. [DOI: 10.1016/j.ijpharm.2014.05.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
23 Baek CK, Choi JY, Kim KA, Park MS, Lim JS, Chung YE, Kim MJ, Kim KW. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol. 2012;67:148-156. [PMID: 21920517 DOI: 10.1016/j.crad.2011.08.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
24 Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging. 2011;36:677-683. [PMID: 21674193 DOI: 10.1007/s00261-011-9755-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
25 Imbriaco M, De Luca S, Coppola M, Fusari M, Klain M, Puglia M, Mainenti P, Liuzzi R, Maurea S. Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma (HCC): A Comparative Study with Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced Computed Tomography (CT). Pol J Radiol. 2017;82:50-57. [PMID: 28217239 DOI: 10.12659/pjr.899239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
26 Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013;163:123-7. [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
27 Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J, Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol. 2012;199:1018-1025. [PMID: 23096174 DOI: 10.2214/ajr.12.8632] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
28 Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Rev Anticancer Ther. 2012;12:1283-1288. [PMID: 23094801 DOI: 10.1586/era.12.102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
29 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
30 Jakobs TF, Hoffmann R, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur Radiol 2007;17:1320-30. [DOI: 10.1007/s00330-006-0508-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
31 Wang Z, Li P, Xu Q, Xu J, Li X, Zhang X, Ma Q, Wu Z. Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell. PLoS One 2013;8:e66659. [PMID: 23825554 DOI: 10.1371/journal.pone.0066659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
32 Ruff SM, Rothermel LD, Diggs LP, Wach MM, Ayabe RI, Martin SP, Boulware D, Anaya D, Davis JL, Mullinax JE, Hernandez JM. Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford) 2020;22:1004-10. [PMID: 31734237 DOI: 10.1016/j.hpb.2019.10.1531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Cai Y, Chang Q, Xiao E, Shang QL, Chen Z. Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e10890. [PMID: 29851811 DOI: 10.1097/MD.0000000000010890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Zhao W, Liu W, Liu H, Yi X, Hou J, Pei Y, Liu H, Feng D, Liu L, Li W. Preoperative prediction of microvascular invasion of hepatocellular carcinoma with IVIM diffusion-weighted MR imaging and Gd-EOB-DTPA-enhanced MR imaging. PLoS One. 2018;13:e0197488. [PMID: 29771954 DOI: 10.1371/journal.pone.0197488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
35 Amesur NB, Zajko AB, Carr BI. Chemo-embolization for Unresectable Hepatocellular Carcinoma with Different Sizes of Embolization Particles. Dig Dis Sci 2008;53:1400-4. [DOI: 10.1007/s10620-007-9995-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zhao Y, Zhang L, Huo L, Pei L, Li Q, Li H, Jin L. Clinical significance of fucosylated GP73 in the differential diagnosis of hepatocellular carcinoma. Int J Biol Markers 2018;33:439-46. [PMID: 30238841 DOI: 10.1177/1724600818796646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee FT Jr. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates. Radiology 2009;253:861-9. [PMID: 19709994 DOI: 10.1148/radiol.2533081968] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 6.4] [Reference Citation Analysis]
38 Zhang S, Li J, Jiang Y, Xu Y, Qin C. Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2009;28:71. [PMID: 19480673 DOI: 10.1186/1756-9966-28-71] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
39 Shi G, Liu C, Yang Y, Song L, Liu X, Wang C, Peng Z, Li H, Zhong L. Panx1 promotes invasion-metastasis cascade in hepatocellular carcinoma. J Cancer 2019;10:5681-8. [PMID: 31737105 DOI: 10.7150/jca.32986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Tam HH, Al-nahhas A. Treatment of liver tumours with yttrium radioembolisation. Clin Transl Imaging 2014;2:165-82. [DOI: 10.1007/s40336-013-0046-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lee SD, Han HS, Cho JY, Yoon YS, Hwang DW, Jung K, Yoon CJ, Kwon Y, Kim JH. Safety and efficacy of laparoscopic radiofrequency ablation for hepatic malignancies. J Korean Surg Soc 2012;83:36-42. [PMID: 22792532 DOI: 10.4174/jkss.2012.83.1.36] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
42 Mehrabi M, Amini F, Mehrabi S. Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages. Front Oncol 2021;11:693076. [PMID: 34557407 DOI: 10.3389/fonc.2021.693076] [Reference Citation Analysis]
43 Erra P, Puglia M, Ragozzino A, Maurea S, Liuzzi R, Sabino G, Barbuto L, Cuocolo A, Imbriaco M. Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review. Radiol Med. 2015;120:1002-1011. [PMID: 25900253 DOI: 10.1007/s11547-015-0539-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
44 Zhang XX, Li HD, Zhao S, Zhao L, Song HJ, Wang G, Guo QJ, Luan ZD, Su RJ. The cell surface GRP78 facilitates the invasion of hepatocellular carcinoma cells. Biomed Res Int 2013;2013:917296. [PMID: 24383061 DOI: 10.1155/2013/917296] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
45 Brennan IM, Ahmed M. Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma. Semin Ultrasound CT MR. 2013;34:336-351. [PMID: 23895906 DOI: 10.1053/j.sult.2013.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Hamie QM, Kobe AR, Mietzsch L, Manhart M, Puippe GD, Pfammatter T, Guggenberger R. Prototype metal artefact reduction algorithm in flat panel computed tomography - evaluation in patients undergoing transarterial hepatic radioembolisation. Eur Radiol 2018;28:265-73. [DOI: 10.1007/s00330-017-4946-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
47 Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol. 2011;34:422-431. [PMID: 20622645 DOI: 10.1097/coc.0b013e3181df0a50] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
48 Lacoeuille F, Hindre F, Moal F, Roux J, Passirani C, Couturier O, Cales P, Le Jeune J, Lamprecht A, Benoit J. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. International Journal of Pharmaceutics 2007;344:143-9. [DOI: 10.1016/j.ijpharm.2007.06.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
49 Kim H, Park MS, Park YN, Kim H, Kim KS, Choi JS, Ahn SH, Han KH, Kim MJ, Kim KW. Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. Yonsei Med J 2009;50:789-95. [PMID: 20046419 DOI: 10.3349/ymj.2009.50.6.789] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
50 Becker AK, Tso DK, Harris AC, Malfair D, Chang SD. Extrahepatic metastases of hepatocellular carcinoma: A spectrum of imaging findings. Can Assoc Radiol J 2014;65:60-6. [PMID: 24239313 DOI: 10.1016/j.carj.2013.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
51 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
52 Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N. Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience. J Gastrointest Cancer 2017;48:321-5. [PMID: 28891006 DOI: 10.1007/s12029-017-9998-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
53 Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res 2021;10:343-52. [PMID: 33442996 DOI: 10.2217/cer-2020-0236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Weinberg BD, Patel RB, Exner AA, Saidel GM, Gao J. Modeling doxorubicin transport to improve intratumoral drug delivery to RF ablated tumors. J Control Release 2007;124:11-9. [PMID: 17900740 DOI: 10.1016/j.jconrel.2007.08.023] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
55 Lam IF, Huang M, Chang MD, Yao PW, Chou YT, Ng SK, Tsai YL, Lin YC, Zhang YF, Yang XY, Lai YK. Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®. Chin Med 2017;12:11. [PMID: 28450884 DOI: 10.1186/s13020-017-0132-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
56 Qin XG, Hua Z, Shuang W, Wang YH, Cui YD. Effects of matrine on HepG2 cell proliferation and expression of tumor relevant proteins in vitro. Pharm Biol 2010;48:275-81. [PMID: 20645813 DOI: 10.3109/13880200903104101] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
57 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 21.1] [Reference Citation Analysis]
58 Bhosale P, Szklaruk J, Silverman PM. Current staging of hepatocellular carcinoma: imaging implications. Cancer Imaging. 2006;6:83-94. [PMID: 16829469 DOI: 10.1102/1470-7330.2006.0014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
59 Geetha A, Saranya P, Annie Jeyachristy S, Surendran R, Sundaram A. Relevance of non-ceruloplasmin copper to oxidative stress in patients with hepatocellular carcinoma. Biol Trace Elem Res 2009;130:229-40. [PMID: 19229483 DOI: 10.1007/s12011-009-8338-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]